×

Midday Movers: Carnival, Chevron, Netflix & more

Wall Street subway station NYSE
Scott Mlyn | CNBC

Take a look at some of Wednesday's midday movers:

Royal Caribbean Cruises - The cruise operator and others including Carnival and Norwegian Cruise Lines Holdings climbed on anticipation that a thaw in U.S.-Cuban relations will increase travel between the two countries.

Herzfeld Caribbean Basin Fund - The fund with $25 million in assets soared on news of the thaw in U.S.-Cuban relations.

Netflix - The provider of online entertainment rose after Dish Network said it would begin streaming Netflix movies and TV shows.

Exxon Mobil - The oil producer and competitors including Chevron ConocoPhillips, Hess and Anadarko Petroleum rallied with crude.

OnDeck Capital - The online arranger of small business loans soared in its market debut.

Amgen - The drug developer climbed after it said its new leukemia treatment would cost about $178,000 when it becomes available on Thursday.

NPS Pharmaceuticals - The drug developer gained after Bloomberg reported Shire was considering a bid for the company.

Blackberry - The maker of wireless devices advanced after it launched its long-awaited Classic smartphone device.

American Express - The credit-card company rose after Morgan Stanley began coverage with an overweight rating.

MasterCard - The company and Visa advanced on news that credit and debit cards can now be used in Cuba.

Diageo - The spirit maker fell after giving a lukewarm outlook for the first half of its fiscal year in the U.S.

Auspex Pharmaceuticals - The drug developer surged after saying said its drug for treating chorea, or involuntary movement associated with Huntington's disease, succeeded in a late-stage study.

Digital River - The provider of cloud-based payment solutions rose after it extended a distribution pact with Microsoft.

The Pantry - The convenience-store chain jumped on a Wall Street Journal report that it was nearing a deal to sell itself.

Joy Global - The mining-equipment maker fell after reporting a four percent drop in quarterly revenue.

Pozen - The company declined after it said two versions of its experimental heart drug were rejected for a second time by the Food and Drug Administration.

(See CNBC's Market Insider Blog)

Questions? Comments? Email us at marketinsider@cnbc.com